Merck brings customers closer to gene therapy product commercialization
- Details
- Category: Merck Group
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection.
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection. The FDA also previously granted Breakthrough Therapy Designation for this application,
AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
- Details
- Category: AbbVie
AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, have announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral immunotherapies.
Pfizer reviewing strategic alternatives for Consumer Healthcare business
- Details
- Category: Pfizer
Pfizer Inc. is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. This announcement is part of Pfizer's continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders.
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. The solution fundamentally changes the way these meetings are organised and conducted.
More Pharma News ...
- Pfizer launches novel programs to put important support services at the fingertips of cancer patients
- Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals
- Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology
- Abbott acquisition of Alere set to close on Tuesday, October 3, 2017
- IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes
- Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
- Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in China